Celularity Inc.(CELU)Earnings, Financials & Key Ratios
CELU•NASDAQ
$0.91
$26M mkt cap·Price updated May 7, 2026
AboutCelularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.Show more
- Revenue$54M+138.1%
- EBITDA-$30M+83.4%
- Net Income-$58M+70.5%
- EPS (Diluted)-2.64+76.0%
- Gross Margin72.36%+143.9%
- EBITDA Margin-56.13%+93.0%
- Operating Margin-70.75%+91.6%
- Net Margin-106.77%+87.6%
- ROE-232.51%-42.1%
- ROIC-31.43%+61.1%
- Debt/Equity7.79+387.7%
- Interest Coverage-6.12+90.4%
CELU Key Insights
Celularity Inc. (CELU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 20.7%
✗Weaknesses
- ✗High debt to equity ratio of 7.8x
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 22.9% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CELU Price & Volume
Celularity Inc. (CELU) stock price & volume — 10-year historical chart
Loading chart...
CELU Growth Metrics
Celularity Inc. (CELU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years20.72%
3 Years36.47%
TTM-15.81%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-130.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-113.06%
Return on Capital
10 Years-52.58%
5 Years-42%
3 Years-49.63%
Last Year-49.31%
CELU Peer Comparison
Celularity Inc. (CELU) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 SANA | 917.92M | 3.50 | -3.02 | -120.02% | 0.38 | |||
 ALLO | 520.77M | 2.27 | -2.61 | -100% | -57.07% | 0.26 | ||
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 |
Compare CELU vs Peers
Celularity Inc. (CELU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CELU Income Statement
Celularity Inc. (CELU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 17.55M | 21.15M | 14.28M | 21.34M | 17.98M | 22.77M | 54.22M | 40.58M |
| Revenue Growth % | - | 20.47% | -32.48% | 49.43% | -15.75% | 26.68% | 138.11% | -15.81% |
| Cost of Goods Sold | 6.55M | 6.32M | 4.93M | 9.65M | 19.66M | 16.02M | 14.99M | 18.16M |
| COGS % of Revenue | 37.34% | 29.9% | 34.54% | 45.24% | 109.4% | 70.34% | 27.64% | - |
| Gross Profit | 11M▲ 0% | 14.82M▲ 34.8% | 9.35M▼ 36.9% | 11.68M▲ 25.0% | -1.69M▼ 114.5% | 6.75M▲ 499.7% | 39.23M▲ 480.8% | 22.42M▲ 0% |
| Gross Margin % | 62.66% | 70.09% | 65.46% | 54.76% | -9.4% | 29.66% | 72.36% | 55.25% |
| Gross Profit Growth % | - | 34.77% | -36.95% | 24.99% | -114.47% | 499.7% | 480.77% | - |
| Operating Expenses | 1.1K | 278.95M | 161.27M | 120.74M | 23.91M | 199.04M | 77.59M | 70.95M |
| OpEx % of Revenue | 0.01% | 1319.11% | 1129.51% | 565.93% | 133.02% | 874.1% | 143.1% | - |
| Selling, General & Admin | 1.1K | 41.79M | 31.34M | 71.34M | 66.02M | 50.58M | 58.64M | 52.26M |
| SG&A % of Revenue | 0.01% | 197.62% | 219.47% | 334.38% | 367.29% | 222.11% | 108.16% | - |
| Research & Development | 29.06M | 46.05M | 52.71M | 88.35M | 78.36M | 30.46M | 17.39M | 15.51M |
| R&D % of Revenue | 165.56% | 217.77% | 369.15% | 414.12% | 435.96% | 133.79% | 32.07% | - |
| Other Operating Expenses | -31.6M | 191.11M | 77.23M | -38.95M | -120.47M | 118M | 1.56M | 1.92M |
| Operating Income | -1.1K▲ 0% | -264.13M▼ 24055364.5% | -151.93M▲ 42.5% | -109.06M▲ 28.2% | -25.6M▲ 76.5% | -192.29M▼ 651.1% | -38.36M▲ 80.1% | -48.53M▲ 0% |
| Operating Margin % | -0.01% | -1249.01% | -1064.05% | -511.17% | -142.42% | -844.44% | -70.75% | -119.6% |
| Operating Income Growth % | - | -24055364.48% | 42.48% | 28.22% | 76.53% | -651.12% | 80.05% | - |
| EBITDA | 4.79M | -257.94M | -143.75M | -100.24M | -16.16M | -182.96M | -30.44M | -41.12M |
| EBITDA Margin % | 27.28% | -1219.76% | -1006.8% | -469.85% | -89.92% | -803.49% | -56.13% | -101.34% |
| EBITDA Growth % | - | -5486.27% | 44.27% | 30.27% | 83.88% | -1031.92% | 83.36% | -454.1% |
| D&A (Non-Cash Add-back) | 4.79M | 6.19M | 8.17M | 8.82M | 9.44M | 9.32M | 7.92M | 7.41M |
| EBIT | -1.1K | -77.16M | -210.58M | -96.93M | -148.27M | -193.27M | -51.63M | -70.97M |
| Net Interest Income | 0 | 694K | -1.98M | -2.84M | 365K | -2.69M | -5.93M | -7.39M |
| Interest Income | 628K | 694K | 370K | 332K | 365K | 320K | 331K | 277K |
| Interest Expense | 0 | 0 | 2.35M | 3.17M | 0 | 3.02M | 6.26M | 7.67M |
| Other Income/Expense | 2 | -3.87M | -61.01M | 8.96M | 39.8M | -4M | -19.53M | -32.12M |
| Pretax Income | -1.1K▲ 0% | -267.99M▼ 24407368.1% | -212.93M▲ 20.5% | -100.1M▲ 53.0% | 14.21M▲ 114.2% | -196.28M▼ 1481.8% | -57.89M▲ 70.5% | -80.65M▲ 0% |
| Pretax Margin % | -0.01% | -1267.29% | -1491.34% | -469.17% | 79.03% | -862% | -106.77% | -198.75% |
| Income Tax | 0 | -56.11M | -4.7M | 20K | 13K | 10K | 0 | -3K |
| Effective Tax Rate % | 0% | 20.94% | 2.21% | -0.02% | 0.09% | -0.01% | 0% | 0% |
| Net Income | -1.1K▲ 0% | -211.88M▼ 19296894.5% | -208.23M▲ 1.7% | -100.12M▲ 51.9% | 14.19M▲ 114.2% | -196.29M▼ 1483.1% | -57.89M▲ 70.5% | -80.64M▲ 0% |
| Net Margin % | -0.01% | -1001.94% | -1458.42% | -469.27% | 78.95% | -862.04% | -106.77% | -198.74% |
| Net Income Growth % | - | -19296894.54% | 1.72% | 51.92% | 114.18% | -1483.14% | 70.51% | -130.07% |
| Net Income (Continuing) | -1.1K | -211.88M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M | -80.64M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00▲ 0% | -88.75▲ 0% | -113.06▼ 27.4% | -14.93▲ 86.8% | 0.95▲ 106.3% | -11.02▼ 1263.4% | -2.64▲ 76.0% | -3.06▲ 0% |
| EPS Growth % | - | - | -27.39% | 86.79% | 106.34% | -1263.4% | 76% | -113.06% |
| EPS (Basic) | 0.00 | -88.75 | -113.06 | -14.93 | 1.01 | -11.02 | -2.64 | - |
| Diluted Shares Outstanding | 3.59M | 2.39M | 1.84M | 6.71M | 14.98M | 17.81M | 21.89M | 26.35M |
| Basic Shares Outstanding | 3.59M | 2.39M | 1.84M | 6.71M | 13.99M | 17.81M | 21.89M | 26.35M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CELU Balance Sheet
Celularity Inc. (CELU) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.71K | 36.81M | 72.16M | 59.1M | 33.5M | 19.79M | 20.56M | 10.6M |
| Cash & Short-Term Investments | 24.71K | 28.13M | 54.31M | 37.24M | 13.97M | 227K | 738K | 120K |
| Cash Only | 24.71K | 28.13M | 54.31M | 37.24M | 13.97M | 227K | 738K | 120K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.92M | 3.08M | 6.55M | 5.23M | 6.97M | 12.12M | 13.56M | 6.71M |
| Days Sales Outstanding | 81.49 | 53.13 | 167.44 | 89.53 | 141.45 | 194.24 | 91.26 | 104.3 |
| Inventory | 3.54M | 3.23M | 3.85M | 9.55M | 5.31M | 5.75M | 5.41M | 2.56M |
| Days Inventory Outstanding | 196.89 | 186.54 | 284.93 | 361.07 | 98.52 | 131.11 | 131.72 | 93.37 |
| Other Current Assets | 1.49M | 480K | 873K | 2K | 1.05M | 0 | 857K | 265K |
| Total Non-Current Assets | 532.17M | 484.69M | 358.85M | 355.03M | 367.56M | 124.1M | 112.12M | 103.64M |
| Property, Plant & Equipment | 4.01M | 66.39M | 90.08M | 90.63M | 88.72M | 78.82M | 72.43M | 67.97M |
| Fixed Asset Turnover | 4.38x | 0.32x | 0.16x | 0.24x | 0.20x | 0.29x | 0.75x | 0.58x |
| Goodwill | 130.64M | 127.07M | 123.3M | 123.3M | 119.69M | 7.35M | 7.35M | 7.35M |
| Intangible Assets | 393.71M | 271.47M | 125.38M | 123.19M | 120.99M | 11M | 9.25M | 8.13M |
| Long-Term Investments | 0 | 291M | 15.2M | 14.84M | 14.84M | 9.94M | 10.24M | 33.34M |
| Other Non-Current Assets | 3.81M | -271.24M | 4.89M | 3.08M | 23.32M | 26.93M | 12.86M | 47.32M |
| Total Assets | 24.71K▲ 0% | 521.5M▲ 2110617.6% | 431.01M▼ 17.4% | 414.13M▼ 3.9% | 401.07M▼ 3.2% | 143.89M▼ 64.1% | 132.68M▼ 7.8% | 114.24M▲ 0% |
| Asset Turnover | 710.49x | 0.04x | 0.03x | 0.05x | 0.04x | 0.16x | 0.41x | 0.33x |
| Asset Growth % | - | 2110617.61% | -17.35% | -3.92% | -3.15% | -64.12% | -7.79% | -40.74% |
| Total Current Liabilities | 150.56K | 20.64M | 26.68M | 26.23M | 62.09M | 67.3M | 53.68M | 65.31M |
| Accounts Payable | 5.27M | 18.88K | 5.39M | 9.32M | 5.81M | 14.14M | 23.3M | 24.59M |
| Days Payables Outstanding | 293.34 | 1.09 | 398.89 | 352.3 | 107.84 | 322.34 | 567.29 | 480.43 |
| Short-Term Debt | 0 | 0 | 3.01M | 3.05M | 37.6M | 39.24M | 6.36M | 5.72M |
| Deferred Revenue (Current) | 0 | 0 | 5.12M | 2.2M | 2.27M | 2.83M | 3.53M | 16.09M |
| Other Current Liabilities | -10.74M | 11.23M | 8.17M | 7.83M | 13.83M | 8.07M | 1.6M | 24.65M |
| Current Ratio | 0.16x | 1.78x | 2.70x | 2.25x | 0.54x | 0.29x | 0.38x | 0.38x |
| Quick Ratio | -23.32x | 1.63x | 2.56x | 1.89x | 0.45x | 0.21x | 0.28x | 0.28x |
| Cash Conversion Cycle | -14.95 | 238.58 | 53.47 | 98.3 | 132.13 | 3.01 | -344.31 | -282.76 |
| Total Non-Current Liabilities | 0 | 363M | 385.62M | 288.48M | 140.08M | 35.63M | 70.17M | 69.02M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 35.93M | 0 |
| Capital Lease Obligations | 0 | 28.06M | 27.63M | 28.09M | 27.98M | 26.18M | 26.55M | 140.94M |
| Deferred Tax Liabilities | 0 | 0 | 7K | 10K | 9K | 9K | 9K | 36K |
| Other Non-Current Liabilities | 0 | 334.94M | 350.36M | 258.52M | 109.86M | 6.26M | 4.96M | 30.39M |
| Total Liabilities | 150.56K | 383.63M | 412.3M | 314.71M | 202.16M | 102.93M | 123.84M | 134.33M |
| Total Debt | 150K | 28.06M | 30.64M | 31.14M | 65.59M | 65.42M | 68.84M | 66.76M |
| Net Debt | 125.29K | -66K | -23.67M | -6.1M | 51.62M | 65.19M | 68.1M | 66.64M |
| Debt / Equity | - | 0.20x | 1.64x | 0.31x | 0.33x | 1.60x | 7.79x | 7.79x |
| Debt / EBITDA | 0.03x | - | - | - | - | - | - | -1.62x |
| Net Debt / EBITDA | 0.03x | - | - | - | - | - | - | -1.62x |
| Interest Coverage | - | - | -64.54x | -34.39x | - | -63.78x | -6.12x | -9.25x |
| Total Equity | -125.85K▲ 0% | 137.86M▲ 109647.3% | 18.71M▼ 86.4% | 99.42M▲ 431.3% | 198.9M▲ 100.1% | 40.96M▼ 79.4% | 8.84M▼ 78.4% | -20.09M▲ 0% |
| Equity Growth % | - | 109647.31% | -86.43% | 431.28% | 100.07% | -79.41% | -78.43% | -604.01% |
| Book Value per Share | -0.04 | 57.75 | 10.16 | 14.83 | 13.28 | 2.30 | 0.40 | -0.76 |
| Total Shareholders' Equity | -125.85K | 137.86M | 18.71M | 99.42M | 198.9M | 40.96M | 8.84M | -20.09M |
| Common Stock | 863 | 1K | 1K | 12K | 15K | 19K | 2K | 3K |
| Retained Earnings | -1.1K | -355.33M | -563.56M | -663.68M | -645.5M | -841.79M | -899.68M | -967.1M |
| Treasury Stock | 0 | 0 | -256K | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -149.75K | 0 | 0 | 0 | 9K | 0 | -5K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CELU Cash Flow Statement
Celularity Inc. (CELU) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -543 | -1.1M | -63.19M | -110.1M | -137.88M | -38.69M | -6.4M | -6.4M |
| Operating CF Margin % | -0% | -5.19% | -442.59% | -516.03% | -767.04% | -169.89% | -11.81% | - |
| Operating CF Growth % | - | -202079.19% | -5656.16% | -74.22% | -25.23% | 71.94% | 83.45% | -2548.42% |
| Net Income | -13.38M | 5.88M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M | -80.64M |
| Depreciation & Amortization | 4.79M | 0 | 8.17M | 8.82M | 9.44M | 11.47M | 7.92M | 7.37M |
| Stock-Based Compensation | 4.5M | 0 | 4.37M | 40.01M | 15.86M | 15.02M | 11.57M | 5.74M |
| Deferred Taxes | 0 | -1.65K | -8.48M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -54.54M | -7.11M | 137.37M | -53.1M | -161.91M | 137.89M | 9.8M | 25.5M |
| Working Capital Changes | -1.34M | 136.39K | 3.6M | -5.71M | -15.45M | -6.77M | 22.2M | 35.48M |
| Change in Receivables | -2.29M | 0 | 1.65M | -1.91M | -3.58M | -6.83M | -3.97M | 1.98M |
| Change in Inventory | -3.4M | 0 | -643K | -6.42M | -16.89M | -865K | 6.28M | 9.15M |
| Change in Payables | 0 | 18.88K | 314K | 0 | 0 | 0 | 9.24M | 9.22M |
| Cash from Investing | -31.18M | -286.85M | -12.81M | -5.9M | -5.24M | -4.05M | 514K | -1.56M |
| Capital Expenditures | -1.92M | 0 | -27.83M | -6.2M | -5.24M | -4.05M | -161K | -56K |
| CapEx % of Revenue | 10.93% | 0% | 194.94% | 29.07% | 29.13% | 17.78% | 0.3% | - |
| Acquisitions | -29.28M | 0 | 15.02M | 0 | 0 | 0 | -1.5M | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 14K | 651K | 0 | 300K | 0 | 0 | 2.17M | -1.5M |
| Cash from Financing | 25.25K | 288.84M | 102.01M | 98.56M | 119.84M | 24.09M | 6.7M | 8.07M |
| Debt Issued (Net) | 0 | -150K | 0 | 0 | 39.2M | 11.31M | 7.1M | -1.07M |
| Equity Issued (Net) | 25K | 1000K | 1000K | 638K | 1000K | 1000K | 58K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -256K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 250 | 0 | -265K | 97.92M | 27.26M | 7.35M | -459K | 1.08M |
| Net Change in Cash | -31.16M▲ 0% | 892.3K▲ 102.9% | 26.01M▲ 2814.5% | -17.44M▼ 167.0% | -23.27M▼ 33.5% | -18.64M▲ 19.9% | 814K▲ 104.4% | -165K▲ 0% |
| Free Cash Flow | -1.92M▲ 0% | -1.1M▲ 42.8% | -91.03M▼ 8191.5% | -116.3M▼ 27.8% | -143.11M▼ 23.1% | -42.73M▲ 70.1% | -6.56M▲ 84.6% | -6.61M▲ 0% |
| FCF Margin % | -10.93% | -5.19% | -637.53% | -545.11% | -796.17% | -187.66% | -12.1% | -16.3% |
| FCF Growth % | - | 42.78% | -8191.54% | -27.76% | -23.06% | 70.14% | 84.64% | 49.21% |
| FCF per Share | -0.53 | -0.46 | -49.42 | -17.34 | -9.55 | -2.40 | -0.30 | -0.30 |
| FCF Conversion (FCF/Net Income) | 0.49x | 0.01x | 0.30x | 1.10x | -9.72x | 0.20x | 0.11x | 0.08x |
| Interest Paid | 0 | 0 | 0 | 146K | 0 | 1.07M | 144K | 0 |
| Taxes Paid | 0 | 0 | 13K | 0 | 0 | 0 | 0 | 0 |
CELU Key Ratios
Celularity Inc. (CELU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -307.66% | -265.99% | -169.5% | 9.51% | -163.67% | -232.51% | 763.31% |
| Return on Invested Capital (ROIC) | -287.52% | -171.55% | -185.14% | -11.17% | -80.87% | -31.43% | -31.43% |
| Gross Margin | 70.09% | 65.46% | 54.76% | -9.4% | 29.66% | 72.36% | 55.25% |
| Net Margin | -1001.94% | -1458.42% | -469.27% | 78.95% | -862.04% | -106.77% | -198.74% |
| Debt / Equity | 0.20x | 1.64x | 0.31x | 0.33x | 1.60x | 7.79x | 7.79x |
| Interest Coverage | - | -64.54x | -34.39x | - | -63.78x | -6.12x | -9.25x |
| FCF Conversion | 0.01x | 0.30x | 1.10x | -9.72x | 0.20x | 0.11x | 0.08x |
| Revenue Growth | 20.47% | -32.48% | 49.43% | -15.75% | 26.68% | 138.11% | -15.81% |
CELU Frequently Asked Questions
Celularity Inc. (CELU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Celularity Inc. (CELU) reported $40.6M in revenue for fiscal year 2024. This represents a 131% increase from $17.6M in 2018.
Celularity Inc. (CELU) grew revenue by 138.1% over the past year. This is strong growth.
Celularity Inc. (CELU) reported a net loss of $80.6M for fiscal year 2024.
Dividend & Returns
Celularity Inc. (CELU) has a return on equity (ROE) of -232.5%. Negative ROE indicates the company is unprofitable.
Celularity Inc. (CELU) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More CELU
Celularity Inc. (CELU) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates